RGS2 Suppresses Breast Cancer Cell Growth via a MCPIP1‐Dependent Pathway

Regulator of G protein signaling 2 (RGS2) is a member of a family of proteins that functions as a GTPase‐activating protein (GAP) for Gα subunits. RGS2 mRNA expression is lower in breast cancerous tissues than in normal tissues. In addition, expression of RGS2 is also lower in MCF7 (cancerous breast cells) than in MCF10A (normal breast cells). Here we investigated whether RGS2 inhibits growth of breast cancer cells. RGS2 overexpression in MCF7 cells inhibited epidermal growth factor‐ or serum‐induced proliferation. In HEK293T cells expressing RGS2, cell growth was also significantly suppressed (In addition, exogenous expression of RGS2 in HEK293T cells resulted in the significant suppression of cell growth). These results suggest that RGS2 may have a tumor suppressor function. MG‐132 treatment of MCF7 cells increased endogenous or exogenous RGS2 levels, suggesting a post‐transcriptional regulatory mechanism that controls RGS2 protein levels. RGS2 protein was degraded polyubiquitinated the K71 residue, but stabilized by deubiquitinase monocyte chemotactic protein‐induced protein 1 (MCPIP1), and not affected by dominant negative mutant (C157A) of MCPIP1. Gene expression profiling study showed that overexpression of RGS2 decreased levels of testis specific Y encoded like protein 5 (TSPYL5), which plays a causal role in breast oncogenesis. TSPYL5 protein expression was low in MCF10A and high in MCF7 cells, showing the opposite aspect to RGS2 expression. Additionally, RGS2 or MCPIP1 overexpression in MCF7 cells decreased TSPYL5 protein level, indicating that RGS2 stabilized by MCPIP1 have diminished TSPYL5 protein levels, thereby exerting an inhibitory effect of breast cancer cell growth. J. Cell. Biochem. 116: 260–267, 2015. © 2014 Wiley Periodicals, Inc.

[1]  Jong-Seon Park,et al.  RGS2 is a negative regulator of STAT3-mediated Nox1 expression. , 2011, Cellular signalling.

[2]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[3]  R. Xiao,et al.  Deregulation of RGS2 in cardiovascular diseases. , 2010, Frontiers in bioscience.

[4]  A. Sharrocks,et al.  Transcription factors Elk-1 and SRF are engaged in IL1-dependent regulation of ZC3H12A expression , 2010, BMC Molecular Biology.

[5]  J. M. Wyss,et al.  Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. , 2003, The Journal of clinical investigation.

[6]  J. Hurst,et al.  Regulator of G-protein signaling (RGS) proteins in cancer biology. , 2009, Biochemical pharmacology.

[7]  P. Lin,et al.  Rgs2 Mediates Pro-Angiogenic Function of Myeloid Derived Suppressor Cells in the Tumor Microenvironment via Upregulation of MCP-1 , 2011, PloS one.

[8]  S. Baek,et al.  Role of JAK2–STAT3 in TLR2‐mediated tissue factor expression , 2013, Journal of cellular biochemistry.

[9]  N. Dulin,et al.  RGS expression in cancer: oncomining the cancer microarray data , 2013, Journal of receptor and signal transduction research.

[10]  L. Skalniak,et al.  Regulatory feedback loop between NF‐κB and MCP‐1‐induced protein 1 RNase , 2009, The FEBS journal.

[11]  Y. E. Chen,et al.  Targeted Disruption of MCPIP1/Zc3h12a Results in Fatal Inflammatory Disease , 2013, Immunology and cell biology.

[12]  A. Ashworth,et al.  Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers , 2007, Breast Cancer Research.

[13]  T. Casale,et al.  Regulator of G protein signaling 2 is a key modulator of airway hyperresponsiveness. , 2012, The Journal of allergy and clinical immunology.

[14]  Jing Wang,et al.  MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-κB signaling , 2010, The Journal of experimental medicine.

[15]  L. Kirshenbaum,et al.  RGS2 inhibits beta-adrenergic receptor-induced cardiomyocyte hypertrophy. , 2010, Cellular signalling.

[16]  Zhihui Xie,et al.  Phosphorylation of RGS13 by the cyclic AMP-dependent protein kinase inhibits RGS13 degradation. , 2010, Journal of molecular cell biology.

[17]  R. Karas,et al.  Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure , 2003, Nature Medicine.

[18]  S. Akira,et al.  mRNA degradation by the endoribonuclease Regnase-1/ZC3H12a/MCPIP-1. , 2013, Biochimica et biophysica acta.

[19]  R. Askeland,et al.  Regulator of G Protein Signaling 6 (RGS6) Induces Apoptosis via a Mitochondrial-dependent Pathway Not Involving Its GTPase-activating Protein Activity* , 2010, The Journal of Biological Chemistry.

[20]  Z. Gatalica,et al.  Epigenetic repression of regulator of G‐protein signaling 2 promotes androgen‐independent prostate cancer cell growth , 2012, International journal of cancer.

[21]  Qin Wang,et al.  Opioid-induced Down-Regulation of RGS4 , 2011, The Journal of Biological Chemistry.

[22]  M. Fu,et al.  A Novel CCCH-Zinc Finger Protein Family Regulates Proinflammatory Activation of Macrophages* , 2008, Journal of Biological Chemistry.

[23]  A. Varshavsky,et al.  RGS4 Is Arginylated and Degraded by the N-end Rule Pathway in Vitro * , 2000, The Journal of Biological Chemistry.

[24]  Zhihui Xie,et al.  RGS16 Inhibits Breast Cancer Cell Growth by Mitigating Phosphatidylinositol 3-Kinase Signaling* , 2009, The Journal of Biological Chemistry.

[25]  Michael Reiss,et al.  MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. , 2009, Cancer cell.

[26]  Haruki Nakamura,et al.  Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay , 2009, Nature.

[27]  W. McGuire,et al.  Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Zoltan Szallasi,et al.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.

[29]  D. Siderovski,et al.  The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits , 2005, International journal of biological sciences.

[30]  Jie Huang,et al.  Regulator of G protein signaling 6 mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism. , 2011, Cancer research.

[31]  Yu Xue,et al.  PPSP: prediction of PK-specific phosphorylation site with Bayesian decision theory , 2006, BMC Bioinformatics.

[32]  René Bernards,et al.  TSPYL5 suppresses p53 levels and function by physical interaction with USP7 , 2011, Nature Cell Biology.

[33]  Mahua Choudhury,et al.  Monocyte Chemoattractant Protein-1 Induces a Novel Transcription Factor That Causes Cardiac Myocyte Apoptosis and Ventricular Dysfunction , 2006, Circulation research.

[34]  R. Neubig,et al.  N-Terminal Residues Control Proteasomal Degradation of RGS2, RGS4, and RGS5 in Human Embryonic Kidney 293 Cells , 2007, Molecular Pharmacology.

[35]  Min Jae Lee,et al.  RGS4 and RGS5 are in vivo substrates of the N-end rule pathway. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  V. Quesada,et al.  Deubiquitinases in cancer: new functions and therapeutic options , 2012, Oncogene.

[37]  R. Neubig,et al.  Cardiotonic Steroids Stabilize Regulator of G Protein Signaling 2 Protein Levels , 2012, Molecular Pharmacology.

[38]  M. Fu,et al.  Genome-Wide Survey and Expression Profiling of CCCH-Zinc Finger Family Reveals a Functional Module in Macrophage Activation , 2008, PloS one.

[39]  S. Gygi,et al.  Alternative ubiquitin activation/conjugation cascades interact with N-end rule ubiquitin ligases to control degradation of RGS proteins. , 2011, Molecular cell.

[40]  R. García-Becerra,et al.  Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance , 2012, International journal of molecular sciences.